Alexia Perouse
Partner, Head of Life Sciences @ Omnes Capital
Paris, France
Alexia Perouse is a Series A investor at Omnes Capital in Paris focused on Health Care and Medical Device. Alexia Perouse is the Co-Founder and CEO at iBionext.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Alexia Perouse invests in
Stages Alexia Perouse invests in
Countries Alexia Perouse invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (54%)
- Medical Device 6 (46%)
- Medical 2 (15%)
- Biotechnology 2 (15%)
- Information Technology 2 (15%)
Stage
- Series A 4 (31%)
- Series B 3 (23%)
- Series C 3 (23%)
- Funding Round 1 (8%)
- Private Equity 1 (8%)
Country
- France 5 (38%)
- United States 1 (8%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tilak is a unique videogame studio where like-minded & passionate people create fun mobile medical games to monitor patients with chronic diseases. | $11M / Oct 12, 2023 | ||
| Tilak is a unique videogame studio where like-minded & passionate people create fun mobile medical games to monitor patients with chronic diseases. | $10.5M / Series A / Oct 12, 2023 | ||
| Tilak is a unique videogame studio where like-minded & passionate people create fun mobile medical games to monitor patients with chronic diseases. | $8.2M / Series A / Oct 28, 2021 | ||
| Pixium Vision is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. The Company intends to harness the rapid advances being made in neural processing, micro-electronics and computing to develop retinal implant systems that forblind people could ultimately provide vision approaching that of a normal healthy Pixium's first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing a sub-retinal implant system (IRIS3), based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2.Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie, and based on collaborative work involving several leading academic teams across Europe. Pixium is backed by a syndicate of blue-chip European venture capital firms including Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure and Polytechnos. | $16.5M / Series A / Nov 25, 2013 | ||
| SuperSonic Imagine SA develops and manufactures ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company provides Aixplorer, an ultrasound system for breast lesion imaging; and ShearWave, an ultrasound technology platform for quantitative elastography. It offers its products through its offices and a networkof distributors in France, Belgium, Austria, Croatia, Poland, the Czech Republic, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Lebanon, Germany, the United Kingdom, and the United States. SuperSonic Imagine SA was founded in 2005 and is based in Aix-en-Provence, France with additional offices in Germany, the United States, and the United Kingdom. | $30.7M / Private Equity / Apr 02, 2013 | ||
| EyeTechCare has developed a new medical device called EyeOP1. This leading edge technology device is the result of several years of joint research with INSERM which has led to the development of a treatment method using High Intensity Focused Ultrasound (HIFU).EyeOP1 is an ultrasound device which offers a non-invasive treatment for refractoryglaucoma. This new method is extremely accurate, simple and only takes one minute. | $11M / Series C / Mar 12, 2013 | ||
| SpineGuard is a French innovative medical company dedicated to the deployment and adoption of DSG® (Dynamic Surgical Guidance), powerful radiation-free real time sensing technology platform that spans a broad spectrum of skeletal applications from bone drilling instruments to automated placement of bone implants. Uniquely positioned to change thegame in orthopedic robotic surgery. Devices, built with the DSG technology, give real-time audio and visual feedback to the surgeons to secure and streamline skeletal implant placement for the benefit of patients, surgeons, operating room staff and healthcare providers. The PediGuard probes are the only devices with built-in DSG capability to improve the accuracy of pedicle screw placement. The PediGuard probes are handheld tools used by spine surgeons to perform pilot holes in the vertebrae before pedicle screw placement. An electrical conductivity measurement sensor, located at the tip of the drilling instruments, alerts the surgeon in real time and without using X-Ray imaging, about changes in conductivity that occur at the transition between cancellous bone, cortical bone and soft tissues/ blood. These devices are used in surgeries for all kind of patients, from pediatric in deformity corrections to adult in degenerative diseases requiring internal fixation. The PediGuard devices are available in different diameters and shapes (straight, curved, cannulated and Threaded). Our new product, The DSG® Connect App, allows collection and visualization on a tab of the signal measured at the tip of DSG Connect devices during pedicle drilling. These medical devices have assisted spine surgeons in accurately placing pedicle screws in over 80,000 spinal procedures around the world. With mounting clinical evidence (16 major Peer-Reviewed publications) confirming its efficacy, PediGuard devices are becoming a compelling answer to the clinical needs associated with safe and accurate pedicle screw placement. | $4.4M / Series B / Sep 27, 2011 | ||
CellNovo
|
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need tomanage their condition.The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes. | $39.3M / Series B / Feb 04, 2011 | |
| SuperSonic Imagine SA develops and manufactures ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company provides Aixplorer, an ultrasound system for breast lesion imaging; and ShearWave, an ultrasound technology platform for quantitative elastography. It offers its products through its offices and a networkof distributors in France, Belgium, Austria, Croatia, Poland, the Czech Republic, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Lebanon, Germany, the United Kingdom, and the United States. SuperSonic Imagine SA was founded in 2005 and is based in Aix-en-Provence, France with additional offices in Germany, the United States, and the United Kingdom. | $37.8M / Series C / Nov 29, 2010 | ||
| CircuLite is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive micro-pumps for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient's native pumping capacity, CircuLite has the potential to improvethe quality of life for millions of chronic heart failure patients and their families. The company's proprietary micro-pump platform enables its PCS devices to be so small that they can be implanted superficially in a pacemaker-like pocket with endovascular or minimally-invasive surgical techniques. | $32.5M / Series C / Jan 05, 2010 | ||
| See all 13 investments → | |||
Co-Investors
About Omnes Capital
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Omnes Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fabien Collangettes
Partner
|
|||
Fabien Prevost
CEO
|
|||
Laurent Perret
Principal & Director of investments
|
|||
Michael Pollan
Investment Director, Renewable Energy
|
|||
Pierre-Axel Botuha
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexia Perouse invest in?
Alexia Perouse invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexia Perouse?
Public channels for Alexia Perouse include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexia Perouse last invest?
The most recent investment recorded for Alexia Perouse closed in Oct 2023. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
